Protein / target
Interferon alpha-2
Protein at a glance
Biological role
Type I interferon receptor binding
Strongest disease association
Carcinoma, Renal Cell
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Produced by macrophages, IFN-alpha have antiviral activities
Subcellular location
Domains and Gene Ontology detail (26)Hide
Gene Ontology
- Cextracellular matrix
- Cextracellular region
- Cextracellular space
- Fcytokine activity
- Ftype I interferon receptor binding
- Padaptive immune response
- Papoptotic process
- PB cell activation involved in immune response
- Pcell surface receptor signaling pathway
- Pcell surface receptor signaling pathway via STAT
- Pcell-cell signaling
- Pcellular response to virus
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·cytokine activity
- ·adaptive immune response
- ·B cell activation involved in immune response
- ·humoral immune response
Transcriptional regulation
- ·negative regulation of DNA-templated transcription
- ·negative regulation of gene expression
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene IFNA2
Gene-level evidence surfaced through the gene IFNA2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 2 approved · 1 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
View underlying tractability evidence (5)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.
Related family literature
Papers about “Interferons” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
via Interferons
via Interferons
via Interferons
via Interferons
via Interferons
via Interferons
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.